Renalytix AI plc focuses on the development of artificial intelligence enabled clinical diagnostic solutions for kidney disease.
+ 1 more risk
Flawless balance sheet with limited growth.
Share Price & News
How has Renalytix AI's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: RENX's share price has been volatile over the past 3 months.
7 Day Return
GB Healthcare Services
1 Year Return
GB Healthcare Services
Return vs Industry: RENX exceeded the UK Healthcare Services industry which returned -21.2% over the past year.
Return vs Market: RENX exceeded the UK Market which returned -22.7% over the past year.
Price Volatility Vs. Market
How volatile is Renalytix AI's share price compared to the market and industry in the last 5 years?
Simply Wall St News
4 months ago | Simply Wall StWhat Kind Of Shareholder Owns Most Renalytix AI plc (LON:RENX) Stock?
8 months ago | Simply Wall StIs There An Opportunity With Renalytix AI plc's (LON:RENX) 27% Undervaluation?
Is Renalytix AI undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate RENX's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate RENX's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: RENX is unprofitable, so we can't compare its PE Ratio to the Healthcare Services industry average.
PE vs Market: RENX is unprofitable, so we can't compare its PE Ratio to the UK market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate RENX's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: RENX is overvalued based on its PB Ratio (3.9x) compared to the GB Healthcare Services industry average (2x).
How is Renalytix AI forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
Forecasted annual revenue growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if RENX's forecast earnings growth is above the savings rate (0.5%).
Earnings vs Market: Insufficient data to determine if RENX's earnings are forecast to grow faster than the UK market
High Growth Earnings: Insufficient data to determine if earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: RENX's revenue (62.7% per year) is forecast to grow faster than the UK market (2.6% per year).
High Growth Revenue: RENX's revenue (62.7% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if RENX's Return on Equity is forecast to be high in 3 years time
How has Renalytix AI performed over the past 5 years?
Last years earnings growth
Earnings and Revenue History
Quality Earnings: RENX is currently unprofitable.
Growing Profit Margin: RENX is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: Unable to establish if RENX's year-on-year earnings growth rate was positive over the past 5 years as it has been trading publicly for less than 3 years.
Accelerating Growth: Unable to compare RENX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: RENX is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare Services industry (-4.6%).
Return on Equity
High ROE: RENX has a negative Return on Equity (-16.54%), as it is currently unprofitable.
How is Renalytix AI's financial position?
Financial Position Analysis
Short Term Liabilities: RENX's short term assets ($21.4M) exceed its short term liabilities ($1.3M).
Long Term Liabilities: RENX has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: RENX is debt free.
Reducing Debt: RENX had no debt 5 years ago.
Inventory Level: RENX has a low level of unsold assets or inventory.
Debt Coverage by Assets: Insufficient data to determine if RENX's debt is covered by short term assets.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: RENX has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: RENX has sufficient cash runway for 2.4 years if free cash flow continues to reduce at historical rates of -66.6% each year.
What is Renalytix AI's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate RENX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate RENX's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if RENX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if RENX's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of RENX's dividend in 3 years as they are not forecast to pay a notable one for the UK market.
How experienced are the management team and are they aligned to shareholders interests?
James McCullough (51yo)
Mr. James R. McCullough, MBA, has been Chief Executive Officer and Director of Renalytix AI plc. Mr. McCullough serves as Director at LungLife AI, Inc. (Cynvenio Biosystems, Inc). Mr. McCullough co-founded ...
CEO Compensation Analysis
Compensation vs Market: James's total compensation ($USD187.34K) is below average for companies of similar size in the UK market ($USD758.23K).
Compensation vs Earnings: Insufficient data to compare James's compensation with company performance.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 33.5%.
Renalytix AI plc's company bio, employee growth, exchange listings and data sources
- Name: Renalytix AI plc
- Ticker: RENX
- Exchange: AIM
- Founded: 2018
- Industry: Health Care Technology
- Sector: Healthcare
- Market Cap: UK£130.715m
- Shares outstanding: 59.42m
- Website: https://www.renalytixai.com
Number of Employees
- Renalytix AI plc
- Avon House
- 19 Stanwell Road
- South Glamorgan
- CF64 2EZ
- United Kingdom
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|RENX||AIM (London Stock Exchange AIM Market)||Yes||Ordinary Shares||GB||GBP||Nov 2018|
|RTNX.F||OTCPK (Pink Sheets LLC)||Yes||Ordinary Shares||US||USD||Nov 2018|
Renalytix AI plc focuses on the development of artificial intelligence enabled clinical diagnostic solutions for kidney disease. Its solutions are used in kidney disease risk assessment, clinical care, patient stratification for drug clinical trials, and drug target discovery. The company was incorporated in 2018 and is headquartered in Cardiff, the United Kingdom. Renalytix AI plc operates independently of EKF Diagnostics Holdings plc as of November 2, 2018.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/03/28 00:24|
|End of Day Share Price||2020/03/27 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.